clinical trial · NCT05503797
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
Fore Biotherapeutics·phase2·recruiting·n = 254
Cancer Harboring BRAF AlterationsHGGLGGSolid TumorsPlixorafenib
brief summary
The objective of this Master Protocol is to evaluate the efficacy and safety of plixorafenib in participants with BRAF altered (BRAF V600E or BRAF fusions) locally advanced or metastatic solid tumors, or recurrent or progressive primary central nervous system (CNS) tumors, including rare BRAF V600E-mutated solid tumors, including anaplastic thyroid, ovarian, cholangiocarcinoma or other rare cancers.
started
Feb 21, 2023
primary completion
Dec 31, 2027
completion
Dec 28, 2028
last updated
Jul 27, 2026
official title
A Phase 2 Master Protocol to Assess the Efficacy and Safety of FORE8394, an Inhibitor of BRAF Class 1 and Class 2 Alterations, in Participants With Cancer Harboring BRAF Alterations
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol